作者: Basal-Ganglia 時(shí)間: 2025-3-21 21:44 作者: Urgency 時(shí)間: 2025-3-22 04:17 作者: 慌張 時(shí)間: 2025-3-22 06:29
Tumor Suppressor Genes,for human cancers (Friend et al. 1986) . The functional groundwork for the efficacy of this avenue of approach came from studies on the genetics of cancer using somatic cell genetics. The first report, in 1969, of the suppression of malignancy in hybrid cells between tumorigenic and nontumorigenic m作者: Substitution 時(shí)間: 2025-3-22 10:43
Oligonucleotide Therapeutics for Human Leukemia,sible for cell growth, development, and neoplastic transformation. With this knowledge has come a natural desire to translate this information into new therapeutic strategies for many of the common maladies which afflict humankind. These include in particular, but are not limited to, cardiovascular,作者: chastise 時(shí)間: 2025-3-22 16:30
Ribozymes as Biotherapeutic Tools for the Modulation of Gene Expression,process of genetic alterations of oncogenes and/or tumor suppressor genes (Foulds 1958; Fearon and Vogelstein 1990). Small molecules interfering with genetic deregulation might become key players in the future search for new anti—cancer drugs. Examples of such molecules include antisense oligonucleo作者: chastise 時(shí)間: 2025-3-22 19:25 作者: 排他 時(shí)間: 2025-3-22 21:29 作者: shrill 時(shí)間: 2025-3-23 03:45 作者: 油膏 時(shí)間: 2025-3-23 07:27 作者: 猛然一拉 時(shí)間: 2025-3-23 13:06
Immunological Approaches for Gene Therapy of Cancer, of tumor immunotherapy. These novel immuno-gene therapies include tumor cell vaccines genetically engineered to express cytokine genes or modified by antisense vectors to inhibit immunosuppressive or differentiation factors, cytokine gene transfer into tumor infiltrating lymphocytes (TILs), intratu作者: Coronary-Spasm 時(shí)間: 2025-3-23 14:46
Gene Therapy Regulatory Issues in the United States and Europe,ene therapy product. The derivation of the rules in the United States and how gene therapy products fit into this will be described. In addition I will discuss interactions with the Food and Drug Administration (FDA), highlighting certain points to keep in mind. Finally a brief overview of European 作者: Optimum 時(shí)間: 2025-3-23 20:55
978-3-662-03579-5Springer-Verlag Berlin Heidelberg 1998作者: follicular-unit 時(shí)間: 2025-3-23 22:10 作者: 圓木可阻礙 時(shí)間: 2025-3-24 04:42 作者: 人類學(xué)家 時(shí)間: 2025-3-24 10:28 作者: Meander 時(shí)間: 2025-3-24 13:48
https://doi.org/10.1007/978-3-319-45252-4nt and cure of human disease has not come to pass several years after the first introduction of DNA into patients for therapeutic purposes. It has been a triumph because it has captured the creative energies and imagination of thousands of scientists throughout the world, has garnered extensive inve作者: 鋼筆記下懲罰 時(shí)間: 2025-3-24 16:02 作者: 磨碎 時(shí)間: 2025-3-24 21:43
ng review anticipated the development of two alternative gene delivery systems: viral gene therapy vectors and synthetic gene delivery systems using purified gene sequences. Theoretical support for the use of viruses arose from the knowledge that DNA and RNA tumor viruses were capable of introducing作者: Hormones 時(shí)間: 2025-3-24 23:48
for human cancers (Friend et al. 1986) . The functional groundwork for the efficacy of this avenue of approach came from studies on the genetics of cancer using somatic cell genetics. The first report, in 1969, of the suppression of malignancy in hybrid cells between tumorigenic and nontumorigenic m作者: 有毒 時(shí)間: 2025-3-25 05:58 作者: 痛苦一生 時(shí)間: 2025-3-25 08:37
https://doi.org/10.1057/9781137313362process of genetic alterations of oncogenes and/or tumor suppressor genes (Foulds 1958; Fearon and Vogelstein 1990). Small molecules interfering with genetic deregulation might become key players in the future search for new anti—cancer drugs. Examples of such molecules include antisense oligonucleo作者: anthropologist 時(shí)間: 2025-3-25 13:33
https://doi.org/10.1057/9780230374591njection of a gene therapeutic curing familial hypercholesterolemia, correcting severe combined immunodeficiency, removing the death sentence from those with a hereditary colon cancer gene, or growing new blood vessels to relieve chronic myocardial ischemia. The last decade has seen much progress to作者: Commodious 時(shí)間: 2025-3-25 18:31
https://doi.org/10.1007/978-1-137-07379-2some instances may be overcome by the use of higher doses (Hryniuk and Bush 1984). Currently available chemotherapy, however, is often associated with various toxicities, in particular, bone marrow toxicity which is limiting for many of these agents. Use of recombinant hematopoietic growth factors o作者: Eeg332 時(shí)間: 2025-3-25 20:44 作者: 手術(shù)刀 時(shí)間: 2025-3-26 03:24 作者: 運(yùn)氣 時(shí)間: 2025-3-26 04:57 作者: 背信 時(shí)間: 2025-3-26 08:55 作者: Trigger-Point 時(shí)間: 2025-3-26 13:34 作者: BAN 時(shí)間: 2025-3-26 20:12 作者: languor 時(shí)間: 2025-3-27 00:30
inant genes into living cells and to permanently transduce them with a new genetic phenotype. During the last 15 years substantial progress has been made to produce safe and effective viral vectors, and we have witnessed an exponential growth in preclinical research and clinical development of recom作者: hauteur 時(shí)間: 2025-3-27 04:05 作者: stroke 時(shí)間: 2025-3-27 08:17
Redefining Frenchness: Thomté Ryam’s , and ar medicine” are discussed. Nevertheless, alternative strategies for treating diseases at the gene level are being developed. The common goal of these various strategies, which are turning out to be as technically demanding as more traditional gene therapy, is to identify disease causing, or disease作者: 忙碌 時(shí)間: 2025-3-27 10:16
https://doi.org/10.1007/978-1-137-07379-2bination with other cytokines, is currently being evaluated in clinical trials. Another means of overcoming myelosuppression is the use of autologous bone marrow or peripheral stem cell transplantation after high doses of chemotherapy. This approach is currently being used in Hodgkin’s disease, brea作者: 豪華 時(shí)間: 2025-3-27 15:30
Citizenship Education and Globalization,tatec—tomy are clinically understaged and are postoperatively found to have tumor extension outside the prostate (Ohori et al. 1995; Paulson 1994; Trapasso et al. 1994; Walsh et al. 1994; Zeitman et al. 1994; Zincke et al. 1994).作者: Mammal 時(shí)間: 2025-3-27 19:37 作者: 都相信我的話 時(shí)間: 2025-3-28 00:48 作者: 高射炮 時(shí)間: 2025-3-28 03:06
Discovery, Development, and Application of Synthetic Gene Delivery Systems,inant genes into living cells and to permanently transduce them with a new genetic phenotype. During the last 15 years substantial progress has been made to produce safe and effective viral vectors, and we have witnessed an exponential growth in preclinical research and clinical development of recom作者: ILEUM 時(shí)間: 2025-3-28 09:01 作者: Immunization 時(shí)間: 2025-3-28 10:54
Oligonucleotide Therapeutics for Human Leukemia,ar medicine” are discussed. Nevertheless, alternative strategies for treating diseases at the gene level are being developed. The common goal of these various strategies, which are turning out to be as technically demanding as more traditional gene therapy, is to identify disease causing, or disease作者: immunity 時(shí)間: 2025-3-28 17:49 作者: 步兵 時(shí)間: 2025-3-28 21:28
Pro-drug Gene Therapy for Prostate Cancer,tatec—tomy are clinically understaged and are postoperatively found to have tumor extension outside the prostate (Ohori et al. 1995; Paulson 1994; Trapasso et al. 1994; Walsh et al. 1994; Zeitman et al. 1994; Zincke et al. 1994).作者: 單挑 時(shí)間: 2025-3-29 00:46 作者: 小畫(huà)像 時(shí)間: 2025-3-29 06:04
https://doi.org/10.1057/978113731336268; Curcio et al. 1997), peptide nucleic acids (Demidov et al. 1993), and aptamers (Stull and Szoka 1995); ribozymes as small RNA molecules with intrinsic specific catalytic activity are one of the most promising candidates for future molecular drugs (Irie et al. 1997).作者: formula 時(shí)間: 2025-3-29 08:38 作者: MILL 時(shí)間: 2025-3-29 11:55
0947-6075 for delivering therapeutic genes to diseased cells, viral and non-viral vector systems, are detailed and characterized. Several reports describe both approaches currently used in gene therapy: the introduction of a wild-type gene to restore normal gene function in diseased cells, and the use of ant作者: 改良 時(shí)間: 2025-3-29 17:33 作者: 解開(kāi) 時(shí)間: 2025-3-29 23:24 作者: 身體萌芽 時(shí)間: 2025-3-30 01:59
0947-6075 ar diseases, using genetic material as therapeutic agents. The regulatory issues governing the use of gene therapy in Europe and the United States are also presented. This book highlights the range of applications and demonstrates the rapid progress being made in the field of gene therapy.978-3-662-03579-5978-3-662-03577-1Series ISSN 0947-6075
